Leap Therapeutics Ownership 2024 | Who Owns Leap Therapeutics Now?


OverviewForecastRevenueFinancialsChart

Institutional Ownership

32.98%

Insider Ownership

14.13%

Retail Ownership

52.88%

Institutional Holders

58.00

Leap Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
JPMORGAN CHASE & CO----3,374-100.00%-Jun 30, 2023
US BANCORP \DE\----6,100-100.00%-Jun 30, 2023
BANK OF AMERICA CORP /DE/----206-100.00%-Jun 30, 2023
WELLS FARGO & COMPANY/MN----641-100.00%-Jun 30, 2023
NORTHERN TRUST CORP----152,931-100.00%-Jun 30, 2023
PRICE T ROWE ASSOCIATES INC /MD/----1,537,227-100.00%-Jun 30, 2023
STATE STREET CORP----177,739-100.00%-Jun 30, 2023
VANGUARD GROUP INC----3,210,802-100.00%-Jun 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----32,000-100.00%-Jun 30, 2023
MORGAN STANLEY----10,334-100.00%-Jun 30, 2023
GROUP ONE TRADING, L.P.----21,240-100.00%-Jun 30, 2023
TOMPKINS FINANCIAL CORP----1,205-100.00%-Jun 30, 2023
RENAISSANCE TECHNOLOGIES LLC----455,200-100.00%-Jun 30, 2023
COMMUNITY TRUST & INVESTMENT CO----13,650-100.00%-Jun 30, 2023
ARTAL GROUP S.A.----4,000,000-100.00%-Jun 30, 2023
D.A. DAVIDSON & CO.----11,000-100.00%-Jun 30, 2023
RAYMOND JAMES & ASSOCIATES----29,678-100.00%-Jun 30, 2023
BRIDGEWAY CAPITAL MANAGEMENT, LLC----298,301-100.00%-Jun 30, 2023
UBS OCONNOR LLC----1,048,685-100.00%-Jun 30, 2023
ADAGE CAPITAL PARTNERS GP, L.L.C.----2,012,180-100.00%-Jun 30, 2023

Leap Therapeutics's largest institutional shareholder is JPMORGAN CHASE & CO, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
JPMORGAN CHASE & CO----3,374-100.00%-Jun 30, 2023
US BANCORP \DE\----6,100-100.00%-Jun 30, 2023
BANK OF AMERICA CORP /DE/----206-100.00%-Jun 30, 2023
WELLS FARGO & COMPANY/MN----641-100.00%-Jun 30, 2023
NORTHERN TRUST CORP----152,931-100.00%-Jun 30, 2023
PRICE T ROWE ASSOCIATES INC /MD/----1,537,227-100.00%-Jun 30, 2023
STATE STREET CORP----177,739-100.00%-Jun 30, 2023
VANGUARD GROUP INC----3,210,802-100.00%-Jun 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----32,000-100.00%-Jun 30, 2023
MORGAN STANLEY----10,334-100.00%-Jun 30, 2023
GROUP ONE TRADING, L.P.----21,240-100.00%-Jun 30, 2023
TOMPKINS FINANCIAL CORP----1,205-100.00%-Jun 30, 2023
RENAISSANCE TECHNOLOGIES LLC----455,200-100.00%-Jun 30, 2023
COMMUNITY TRUST & INVESTMENT CO----13,650-100.00%-Jun 30, 2023
ARTAL GROUP S.A.----4,000,000-100.00%-Jun 30, 2023
D.A. DAVIDSON & CO.----11,000-100.00%-Jun 30, 2023
RAYMOND JAMES & ASSOCIATES----29,678-100.00%-Jun 30, 2023
BRIDGEWAY CAPITAL MANAGEMENT, LLC----298,301-100.00%-Jun 30, 2023
UBS OCONNOR LLC----1,048,685-100.00%-Jun 30, 2023
ADAGE CAPITAL PARTNERS GP, L.L.C.----2,012,180-100.00%-Jun 30, 2023

The largest Leap Therapeutics shareholder by % of total assets is JPMORGAN CHASE & CO. The company owns 0.00 shares of Leap Therapeutics (LPTX), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
FOCUSED WEALTH MANAGEMENT, INC----70-100.00%-Jun 30, 2023
TCI WEALTH ADVISORS, INC.----200-100.00%-Jun 30, 2023
BANK OF AMERICA CORP /DE/----206-100.00%-Jun 30, 2023
WELLS FARGO & COMPANY/MN----641-100.00%-Jun 30, 2023
ALLWORTH FINANCIAL LP----1,150-100.00%-Jun 30, 2023
TOMPKINS FINANCIAL CORP----1,205-100.00%-Jun 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----2,083-100.00%-Jun 30, 2023
JPMORGAN CHASE & CO----3,374-100.00%-Jun 30, 2023
US BANCORP \DE\----6,100-100.00%-Jun 30, 2023
CAPTRUST FINANCIAL ADVISORS----10,000-100.00%-Jun 30, 2023
DONALDSON CAPITAL MANAGEMENT, LLC----10,000-100.00%-Jun 30, 2023
JANE STREET GROUP, LLC----10,008-100.00%-Jun 30, 2023
MORGAN STANLEY----10,334-100.00%-Jun 30, 2023
D.A. DAVIDSON & CO.----11,000-100.00%-Jun 30, 2023
MILLENNIUM MANAGEMENT LLC----12,670-100.00%-Jun 30, 2023
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.----12,878-100.00%-Jun 30, 2023
UBS GROUP AG----13,064-100.00%-Jun 30, 2023
COMMUNITY TRUST & INVESTMENT CO----13,650-100.00%-Jun 30, 2023
BAYSTATE WEALTH MANAGEMENT LLC----15,385-100.00%-Jun 30, 2023
VALEO FINANCIAL ADVISORS, LLC----15,635-100.00%-Jun 30, 2023

As of Jun 30 2023, Leap Therapeutics's largest institutional buyer is FOCUSED WEALTH MANAGEMENT, INC. The company purchased -70.00 stocks of LPTX, valued at -.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BAKER BROS. ADVISORS LP----7,425,570-100.00%-Jun 30, 2023
PERCEPTIVE ADVISORS LLC----6,726,496-100.00%-Jun 30, 2023
ROCK SPRINGS CAPITAL MANAGEMENT LP----4,655,186-100.00%-Jun 30, 2023
ARTAL GROUP S.A.----4,000,000-100.00%-Jun 30, 2023
VANGUARD GROUP INC----3,210,802-100.00%-Jun 30, 2023
683 CAPITAL MANAGEMENT, LLC----2,800,000-100.00%-Jun 30, 2023
ADAGE CAPITAL PARTNERS GP, L.L.C.----2,012,180-100.00%-Jun 30, 2023
PRICE T ROWE ASSOCIATES INC /MD/----1,537,227-100.00%-Jun 30, 2023
KEY CLIENT FIDUCIARY ADVISORS, LLC----1,535,816-100.00%-Jun 30, 2023
CORMORANT ASSET MANAGEMENT, LP----1,481,511-100.00%-Jun 30, 2023
UBS OCONNOR LLC----1,048,685-100.00%-Jun 30, 2023
CITADEL ADVISORS LLC----1,046,712-100.00%-Jun 30, 2023
SAMSARA BIOCAPITAL, LLC----846,038-100.00%-Jun 30, 2023
BLACKROCK INC.----619,013-100.00%-Jun 30, 2023
GEODE CAPITAL MANAGEMENT, LLC----618,673-100.00%-Jun 30, 2023
KNOTT DAVID M JR----557,939-100.00%-Jun 30, 2023
RENAISSANCE TECHNOLOGIES LLC----455,200-100.00%-Jun 30, 2023
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.----453,441-100.00%-Jun 30, 2023
BRIDGEWAY CAPITAL MANAGEMENT, LLC----298,301-100.00%-Jun 30, 2023
PLATINUM INVESTMENT MANAGEMENT LTD----264,413-100.00%-Jun 30, 2023

As of Jun 30 2023, Leap Therapeutics's biggest institutional seller is BAKER BROS. ADVISORS LP. The company sold -7.43M shares of LPTX, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BAKER BROS. ADVISORS LP----7,425,570-100.00%-Jun 30, 2023
PERCEPTIVE ADVISORS LLC----6,726,496-100.00%-Jun 30, 2023
ROCK SPRINGS CAPITAL MANAGEMENT LP----4,655,186-100.00%-Jun 30, 2023
ARTAL GROUP S.A.----4,000,000-100.00%-Jun 30, 2023
VANGUARD GROUP INC----3,210,802-100.00%-Jun 30, 2023
683 CAPITAL MANAGEMENT, LLC----2,800,000-100.00%-Jun 30, 2023
ADAGE CAPITAL PARTNERS GP, L.L.C.----2,012,180-100.00%-Jun 30, 2023
PRICE T ROWE ASSOCIATES INC /MD/----1,537,227-100.00%-Jun 30, 2023
KEY CLIENT FIDUCIARY ADVISORS, LLC----1,535,816-100.00%-Jun 30, 2023
CORMORANT ASSET MANAGEMENT, LP----1,481,511-100.00%-Jun 30, 2023
UBS OCONNOR LLC----1,048,685-100.00%-Jun 30, 2023
CITADEL ADVISORS LLC----1,046,712-100.00%-Jun 30, 2023
SAMSARA BIOCAPITAL, LLC----846,038-100.00%-Jun 30, 2023
BLACKROCK INC.----619,013-100.00%-Jun 30, 2023
GEODE CAPITAL MANAGEMENT, LLC----618,673-100.00%-Jun 30, 2023
KNOTT DAVID M JR----557,939-100.00%-Jun 30, 2023
RENAISSANCE TECHNOLOGIES LLC----455,200-100.00%-Jun 30, 2023
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.----453,441-100.00%-Jun 30, 2023
BRIDGEWAY CAPITAL MANAGEMENT, LLC----298,301-100.00%-Jun 30, 2023
PLATINUM INVESTMENT MANAGEMENT LTD----264,413-100.00%-Jun 30, 2023
ADVISOR GROUP HOLDINGS, INC.----183,895-100.00%-Jun 30, 2023
STATE STREET CORP----177,739-100.00%-Jun 30, 2023
NORTHERN TRUST CORP----152,931-100.00%-Jun 30, 2023
SCHONFELD STRATEGIC ADVISORS LLC----50,700-100.00%-Jun 30, 2023
MCADAM, LLC----45,778-100.00%-Jun 30, 2023
ANNANDALE CAPITAL, LLC----40,000-100.00%-Jun 30, 2023
TWO SIGMA INVESTMENTS, LP----39,790-100.00%-Jun 30, 2023
BANK OF NEW YORK MELLON CORP----35,483-100.00%-Jun 30, 2023
CHARLES SCHWAB INVESTMENT MANAGEMENT INC----32,000-100.00%-Jun 30, 2023
RAYMOND JAMES & ASSOCIATES----29,678-100.00%-Jun 30, 2023
TWO SIGMA ADVISERS, LP----27,400-100.00%-Jun 30, 2023
LPL FINANCIAL LLC----26,375-100.00%-Jun 30, 2023
JANNEY MONTGOMERY SCOTT LLC----25,000-100.00%-Jun 30, 2023
GROUP ONE TRADING, L.P.----21,240-100.00%-Jun 30, 2023
ROCKEFELLER CAPITAL MANAGEMENT L.P.----17,000-100.00%-Jun 30, 2023
CNB BANK----16,000-100.00%-Jun 30, 2023
VALEO FINANCIAL ADVISORS, LLC----15,635-100.00%-Jun 30, 2023
BAYSTATE WEALTH MANAGEMENT LLC----15,385-100.00%-Jun 30, 2023
COMMUNITY TRUST & INVESTMENT CO----13,650-100.00%-Jun 30, 2023
UBS GROUP AG----13,064-100.00%-Jun 30, 2023
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.----12,878-100.00%-Jun 30, 2023
MILLENNIUM MANAGEMENT LLC----12,670-100.00%-Jun 30, 2023
D.A. DAVIDSON & CO.----11,000-100.00%-Jun 30, 2023
MORGAN STANLEY----10,334-100.00%-Jun 30, 2023
JANE STREET GROUP, LLC----10,008-100.00%-Jun 30, 2023
DONALDSON CAPITAL MANAGEMENT, LLC----10,000-100.00%-Jun 30, 2023
CAPTRUST FINANCIAL ADVISORS----10,000-100.00%-Jun 30, 2023
US BANCORP \DE\----6,100-100.00%-Jun 30, 2023
JPMORGAN CHASE & CO----3,374-100.00%-Jun 30, 2023
TOWER RESEARCH CAPITAL LLC (TRC)----2,083-100.00%-Jun 30, 2023
TOMPKINS FINANCIAL CORP----1,205-100.00%-Jun 30, 2023
ALLWORTH FINANCIAL LP----1,150-100.00%-Jun 30, 2023
WELLS FARGO & COMPANY/MN----641-100.00%-Jun 30, 2023
BANK OF AMERICA CORP /DE/----206-100.00%-Jun 30, 2023
TCI WEALTH ADVISORS, INC.----200-100.00%-Jun 30, 2023
FOCUSED WEALTH MANAGEMENT, INC----70-100.00%-Jun 30, 2023

Leap Therapeutics's largest sold out institutional shareholder by shares sold is BAKER BROS. ADVISORS LP, sold -7.43M shares, valued at -, as of undefined.

Leap Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
BRIDGEWAY FUNDS INC0.12%288,301--Dec 29, 2023
T. Rowe Price Health Sciences Fund, Inc.0.06%317,469--Dec 31, 2023
Vericimetry Funds0.06%6,320--Dec 31, 2023
T. Rowe Price New Horizons Fund, Inc.0.02%359,193--Dec 31, 2023
BRIDGEWAY FUNDS INC0.01%28,830--Dec 29, 2023
T. Rowe Price Equity Series, Inc.0.01%15,196--Dec 31, 2023
T. Rowe Price Health Sciences Fund, Inc.0.01%43,400--Dec 31, 2023
VANGUARD INDEX FUNDS0.01%3,141,141--Dec 31, 2023
T. Rowe Price Small-Cap Stock Fund, Inc.0.00%17,800--Dec 31, 2023
T. Rowe Price New Horizons Fund, Inc.0.00%62,500--Dec 31, 2023
FIDELITY SELECT PORTFOLIOS0.00%254,900--Feb 29, 2024
FIDELITY CONCORD STREET TRUST0.00%628,980--Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%50,658--Dec 31, 2023
VANGUARD INDEX FUNDS0.00%560,786226,07367.54%Dec 31, 2023
T. Rowe Price Equity Series, Inc.0.00%1,900--Dec 31, 2023
VANGUARD VALLEY FORGE FUNDS0.00%400--Dec 31, 2023
SCHWAB CAPITAL TRUST0.00%32,000--Feb 29, 2024
T. Rowe Price Equity Funds, Inc.0.00%9,500--Dec 31, 2023
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%5,065--Dec 31, 2023
NATIONWIDE MUTUAL FUNDS0.00%20,000--Jan 31, 2024
VALIC Co I0.00%39,500--Feb 29, 2024
AMERICAN CENTURY ETF TRUST0.00%10,36010,360-Feb 29, 2024
SCHWAB CAPITAL TRUST0.00%3,200--Feb 29, 2024
T. Rowe Price Spectrum Funds II, Inc.0.00%700--Feb 29, 2024
PACE SELECT ADVISORS TRUST0.00%12,500--Jan 31, 2024
PROSHARES TRUST0.00%8,328--Feb 29, 2024
AMERICAN CENTURY ETF TRUST0.00%1,240--Feb 29, 2024
EQ ADVISORS TRUST0.00%11,719--Dec 31, 2023
iSHARES TRUST0.00%159,447--Feb 29, 2024
DFA INVESTMENT DIMENSIONS GROUP INC0.00%7,618--Jan 31, 2024
Dimensional ETF Trust0.00%1,872--Jan 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%2,727--Dec 31, 2023
MASSMUTUAL SELECT FUNDS0.00%1,256--Dec 31, 2023
EQ ADVISORS TRUST0.00%200--Dec 31, 2023

Leap Therapeutics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 288.30K shares, compromising 0.12% of its total assets.

Leap Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 2358-1.69%
31 Dec, 2259-11.94%
30 Sep, 2267-5.63%
30 Jun, 2271-14.46%
31 Mar, 22833.75%
31 Dec, 218029.03%
30 Sep, 216258.97%
30 Jun, 2139-11.36%
31 Mar, 2144-4.35%
31 Dec, 204621.05%
30 Sep, 2038-17.39%
30 Jun, 2046109.09%
31 Mar, 202269.23%
31 Dec, 1913-27.78%
30 Sep, 191838.46%
30 Jun, 191318.18%
31 Mar, 1911-35.29%
31 Dec, 1817-26.09%
30 Sep, 182315.00%
30 Jun, 18205.26%
31 Mar, 181935.71%
31 Dec, 171475.00%
30 Sep, 17833.33%
30 Jun, 17620.00%
31 Mar, 175-

As of 31 Mar 23, 58 institutions are holding Leap Therapeutics's shares, representing a decrease of -1.69% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 2342,663,86531.01%
31 Dec, 2232,566,398-11.82%
30 Sep, 2236,931,918-1.56%
30 Jun, 2237,517,087-12.78%
31 Mar, 2243,015,3000.67%
31 Dec, 2142,729,9332.05%
30 Sep, 2141,873,49693.90%
30 Jun, 2121,594,913-4.30%
31 Mar, 2122,565,316-7.37%
31 Dec, 2024,361,115-1.77%
30 Sep, 2024,800,729-11.64%
30 Jun, 2028,068,946150.56%
31 Mar, 2011,202,316239.87%
31 Dec, 193,296,087-12.67%
30 Sep, 193,774,13144.90%
30 Jun, 192,604,68823.82%
31 Mar, 192,103,5448.88%
31 Dec, 181,932,011-15.31%
30 Sep, 182,281,180-13.11%
30 Jun, 182,625,3936.33%
31 Mar, 182,469,039606.53%
31 Dec, 17349,462188.25%
30 Sep, 17121,23560.12%
30 Jun, 1775,716-8.22%
31 Mar, 1782,497-

Leap Therapeutics (LPTX) has 42.66M shares outstanding as of 31 Mar 23, up 31.01% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 2332.98%3.99%
31 Dec, 2228.76%2.70%
30 Sep, 2232.61%2.97%
30 Jun, 2233.13%2.30%
31 Mar, 2237.98%2.66%
31 Dec, 2137.78%1.32%
30 Sep, 2153.53%6.70%
30 Jun, 2128.27%3.24%
31 Mar, 2129.54%1.75%
31 Dec, 2041.06%3.89%
30 Sep, 2032.49%1.13%
30 Jun, 2053.52%4.27%
31 Mar, 2035.41%16.62%
31 Dec, 1914.60%5.86%
30 Sep, 1915.78%12.20%
30 Jun, 1911.37%9.51%
31 Mar, 1910.93%5.86%
31 Dec, 1813.66%5.67%
30 Sep, 1815.52%4.86%
30 Jun, 1817.87%4.54%
31 Mar, 1819.83%192.06%
31 Dec, 173.21%193.02%
30 Sep, 171.29%198.52%
30 Jun, 170.81%57.14%
31 Mar, 171.19%-

As of 31 Mar 23, Leap Therapeutics is held by 32.98% institutional shareholders, representing a 3.99% growth compared to 31 Dec 22.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 23244.35%
31 Dec, 2223-11.54%
30 Sep, 2226-
30 Jun, 2226-39.53%
31 Mar, 2243-18.87%
31 Dec, 215312.77%
30 Sep, 2147291.67%
30 Jun, 2112-40.00%
31 Mar, 2120-35.48%
31 Dec, 203129.17%
30 Sep, 2024-36.84%
30 Jun, 2038153.33%
31 Mar, 2015400.00%
31 Dec, 193-72.73%
30 Sep, 191137.50%
30 Jun, 198-11.11%
31 Mar, 199-10.00%
31 Dec, 1810-33.33%
30 Sep, 181525.00%
30 Jun, 1812-7.69%
31 Mar, 181318.18%
31 Dec, 1711175.00%
30 Sep, 17433.33%
30 Jun, 173-40.00%
31 Mar, 175-

24 institutional shareholders have increased their position in LPTX stock as of 31 Mar 23 compared to 23 in the previous quarter (a 4.35% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 23147.69%
31 Dec, 2213-
30 Sep, 2213-27.78%
30 Jun, 221828.57%
31 Mar, 2214100.00%
31 Dec, 217-
30 Sep, 217-41.67%
30 Jun, 2112-20.00%
31 Mar, 2115114.29%
31 Dec, 207-30.00%
30 Sep, 2010900.00%
30 Jun, 201-
31 Mar, 201-66.67%
31 Dec, 19350.00%
30 Sep, 192-
30 Jun, 19--
31 Mar, 19--100.00%
31 Dec, 183-40.00%
30 Sep, 185150.00%
30 Jun, 182-
31 Mar, 182-
31 Dec, 17--100.00%
30 Sep, 171-
30 Jun, 171-
31 Mar, 17--

14 institutional shareholders have reduced their position in LPTX stock as of 31 Mar 23 compared to 13 in the previous quarter (a 7.69% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 2358-1.69%42,663,86531.01%32.98%3.99%244.35%147.69%
31 Dec, 2259-11.94%32,566,398-11.82%28.76%2.70%23-11.54%13-
30 Sep, 2267-5.63%36,931,918-1.56%32.61%2.97%26-13-27.78%
30 Jun, 2271-14.46%37,517,087-12.78%33.13%2.30%26-39.53%1828.57%
31 Mar, 22833.75%43,015,3000.67%37.98%2.66%43-18.87%14100.00%
31 Dec, 218029.03%42,729,9332.05%37.78%1.32%5312.77%7-
30 Sep, 216258.97%41,873,49693.90%53.53%6.70%47291.67%7-41.67%
30 Jun, 2139-11.36%21,594,913-4.30%28.27%3.24%12-40.00%12-20.00%
31 Mar, 2144-4.35%22,565,316-7.37%29.54%1.75%20-35.48%15114.29%
31 Dec, 204621.05%24,361,115-1.77%41.06%3.89%3129.17%7-30.00%
30 Sep, 2038-17.39%24,800,729-11.64%32.49%1.13%24-36.84%10900.00%
30 Jun, 2046109.09%28,068,946150.56%53.52%4.27%38153.33%1-
31 Mar, 202269.23%11,202,316239.87%35.41%16.62%15400.00%1-66.67%
31 Dec, 1913-27.78%3,296,087-12.67%14.60%5.86%3-72.73%350.00%
30 Sep, 191838.46%3,774,13144.90%15.78%12.20%1137.50%2-
30 Jun, 191318.18%2,604,68823.82%11.37%9.51%8-11.11%--
31 Mar, 1911-35.29%2,103,5448.88%10.93%5.86%9-10.00%--100.00%
31 Dec, 1817-26.09%1,932,011-15.31%13.66%5.67%10-33.33%3-40.00%
30 Sep, 182315.00%2,281,180-13.11%15.52%4.86%1525.00%5150.00%
30 Jun, 18205.26%2,625,3936.33%17.87%4.54%12-7.69%2-
31 Mar, 181935.71%2,469,039606.53%19.83%192.06%1318.18%2-
31 Dec, 171475.00%349,462188.25%3.21%193.02%11175.00%--100.00%
30 Sep, 17833.33%121,23560.12%1.29%198.52%433.33%1-
30 Jun, 17620.00%75,716-8.22%0.81%57.14%3-40.00%1-
31 Mar, 175-82,497-1.19%-5---

Leap Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 19, 2024GILEAD SCIENCES, INC.10 percent owner-Sell---5,319,148
Jan 30, 2024Mirabelli Christopherdirector, officer Chairman of the BoardM-ExemptSell5,000---
Jan 30, 2024O'Mahony John Markofficer Chief Manufacturing OfficerM-ExemptSell5,000---

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 19, 2024GILEAD SCIENCES, INC.10 percent owner-Sell---5,319,148
Jan 31, 2024Mashiach Nissimdirector-A-AwardBuy25,000$2.68$67.00K25,000
Jan 31, 2024Dietz Thomas Johndirector-A-AwardBuy30,000$2.68$80.40K30,000
Jan 31, 2024Schilsky Richarddirector-A-AwardBuy25,000$2.68$67.00K25,000
Jan 31, 2024Granfield Christineofficer VP, Head of Reg Affairs/QualA-AwardBuy85,000$2.68$227.80K85,000
Jan 31, 2024Baum Jasonofficer Chief Scientific OfficerA-AwardBuy85,000$2.68$227.80K85,000
Jan 31, 2024Richard Christian Mdirector-A-AwardBuy25,000$2.68$67.00K25,000
Jan 31, 2024O'Mahony John Markofficer Chief Manufacturing OfficerA-AwardBuy85,000$2.68$227.80K85,000
Jan 31, 2024Sirard Cynthiaofficer Chief Medical OfficerA-AwardBuy85,000$2.68$227.80K85,000
Jan 31, 2024Martin Patricia A.director-A-AwardBuy25,000$2.68$67.00K25,000
Jan 31, 2024LAWLOR AUGUSTINEofficer Chief Operating OfficerA-AwardBuy85,000$2.68$227.80K85,000
Jan 31, 2024LOSCALZO JOSEPHdirector-A-AwardBuy25,000$2.68$67.00K25,000
Jan 31, 2024Mirabelli Christopherdirector, officer Chairman of the BoardA-AwardBuy85,000$2.68$227.80K85,000
Jan 31, 2024ONSI DOUGLAS Edirector, officer CEO,CFO,Pres.,GC,Treas.,&Sec.A-AwardBuy170,000$2.68$455.60K170,000
Jan 31, 2024LI WILLIAMdirector-A-AwardBuy25,000$2.68$67.00K25,000
Jan 31, 2024CAVANAUGH JAMES Hdirector-A-AwardBuy25,000$2.68$67.00K25,000
Jan 30, 2024Mirabelli Christopherdirector, officer Chairman of the BoardM-ExemptBuy5,000--5,086
Jan 30, 2024Mirabelli Christopherdirector, officer Chairman of the BoardM-ExemptSell5,000---
Jan 30, 2024O'Mahony John Markofficer Chief Manufacturing OfficerM-ExemptBuy5,000--5,000
Jan 30, 2024O'Mahony John Markofficer Chief Manufacturing OfficerM-ExemptSell5,000---

The last insider sell of Leap Therapeutics's stock was made by GILEAD SCIENCES, INC. on Apr 19 2024, selling - shares at - per share (valued at -).

Leap Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 202315--
Q2 2023-6-
Q1 20231511500.00%
Q3 202212--
Q1 202212--
Q3 20214--
Q2 20216--
Q1 2021204500.00%
Q4 2020-1-
Q3 20201011000.00%
Q2 2020102050.00%
Q1 202082400.00%
Q2 20199--
Q1 201917--
Q4 2018---
Q3 201871700.00%
Q2 20189--
Q4 201782400.00%
Q1 2017137185.71%

15 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Leap Therapeutics's insiders, as of Q3 2023.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 2023---
Q2 2023---
Q1 2023---
Q3 2022---
Q1 2022---
Q3 20212--
Q2 2021---
Q1 2021---
Q4 2020---
Q3 2020---
Q2 20201--
Q1 2020---
Q2 2019---
Q1 20198--
Q4 2018---
Q3 2018---
Q2 2018---
Q4 20178--
Q1 2017---

As of Q3 2023, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Leap Therapeutics's stocks.

Leap Therapeutics Peer Ownership


TickerCompany
TERNTerns Pharmaceuticals, Inc.
ABOSAcumen Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
ELEVElevation Oncology, Inc.
XFORX4 Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
DAWNDay One Biopharmaceuticals, Inc.
PDSBPDS Biotechnology Corporation
EFTReFFECTOR Therapeutics, Inc.
HOOKHOOKIPA Pharma Inc.
HEPAHepion Pharmaceuticals, Inc.

LPTX Ownership FAQ


Leap Therapeutics is owned by institutional shareholders (32.98%), insiders (14.13%), and public (52.88%). The largest institutional shareholder of Leap Therapeutics is JPMORGAN CHASE & CO (0% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.12% of total shares).

Leap Therapeutics's major institutional shareholders are JPMORGAN CHASE & CO, US BANCORP \DE\, BANK OF AMERICA CORP /DE/, WELLS FARGO & COMPANY/MN, and NORTHERN TRUST CORP. The top five shareholders own together 0% of the company's share outstanding.

As of Mar 2023, there are 58 institutional shareholders of Leap Therapeutics.

JPMORGAN CHASE & CO owns 0 shares of Leap Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Jun 2023).

As of Jun 2023, US BANCORP \DE\ holds 0 shares of Leap Therapeutics (LPTX), compromising 0% of the company, valued at $0.

BANK OF AMERICA CORP /DE/ is the third largest holder of Leap Therapeutics. The company owns 0 of the company's shares outstanding (worth $0).